Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.

NCT00004935 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00004935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Terminated
Start date
August 30, 1999
Completion date
March 31, 2022
Enrollment
175 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer